Company intelligence / Profile preview

Everist Genomics

Ann Arbor, Michigan, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

Everist Genomics has developed and commercialized several companion diagnostics aimed at early detection and management of colorectal cancer and cardiovascular disease. Their AngioDefender device has been clinically validated to assess vascular health non-invasively. Clinical studies have demonstrated comparability to established ultrasound imaging techniques in quantifying vascular function.

Therapeutic areas: Metabolic DisordersCardiovascularOncology
Modalities: DeviceDiagnostic testPrognostic testTherapeutic selection technology
Industry: Molecular Diagnostics

Partnerships

Manipal Group joint venture targeting Indian marketlab presence at Johnson & Johnson's Janssen Labs innovation center in San Diego

Beyond the preview

Go deeper on Everist Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Everist Genomics.

Explore the full profile